Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer
N
Shared by NobleBlocks on Aug 28, 2023 • 12:00 AM UTC
Authors:
Weihao Li
,
Chi Zhou
,
Long Yu
Finding related papers...
Discussions
(0)
No comments yet
Be the first to share your thoughts!
Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer | NobleBlocks
